|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SDR42E1 |
Gene summary for SDR42E1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SDR42E1 | Gene ID | 93517 |
| Gene name | short chain dehydrogenase/reductase family 42E, member 1 | |
| Gene Alias | HSPC105 | |
| Cytomap | 16q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q8WUS8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 93517 | SDR42E1 | C04 | Human | Oral cavity | OSCC | 9.61e-11 | 5.96e-01 | 0.2633 |
| 93517 | SDR42E1 | C21 | Human | Oral cavity | OSCC | 1.11e-19 | 5.27e-01 | 0.2678 |
| 93517 | SDR42E1 | C30 | Human | Oral cavity | OSCC | 7.32e-12 | 5.66e-01 | 0.3055 |
| 93517 | SDR42E1 | C43 | Human | Oral cavity | OSCC | 8.53e-03 | 1.10e-01 | 0.1704 |
| 93517 | SDR42E1 | C46 | Human | Oral cavity | OSCC | 5.74e-08 | 2.06e-01 | 0.1673 |
| 93517 | SDR42E1 | C57 | Human | Oral cavity | OSCC | 1.27e-02 | 1.65e-01 | 0.1679 |
| 93517 | SDR42E1 | C08 | Human | Oral cavity | OSCC | 2.61e-06 | 1.56e-01 | 0.1919 |
| 93517 | SDR42E1 | LN46 | Human | Oral cavity | OSCC | 1.24e-05 | 2.35e-01 | 0.1666 |
| 93517 | SDR42E1 | SYSMH2 | Human | Oral cavity | OSCC | 2.38e-02 | 1.46e-01 | 0.2326 |
| 93517 | SDR42E1 | SYSMH3 | Human | Oral cavity | OSCC | 8.79e-12 | 3.28e-01 | 0.2442 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00066945 | Oral cavity | OSCC | steroid biosynthetic process | 89/7305 | 173/18723 | 5.77e-04 | 3.30e-03 | 89 |
| GO:00082024 | Oral cavity | OSCC | steroid metabolic process | 146/7305 | 319/18723 | 7.78e-03 | 2.85e-02 | 146 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SDR42E1 | SNV | Missense_Mutation | c.1076N>T | p.Ser359Phe | p.S359F | Q8WUS8 | protein_coding | tolerated(0.15) | benign(0) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| SDR42E1 | SNV | Missense_Mutation | c.142N>A | p.Pro48Thr | p.P48T | Q8WUS8 | protein_coding | deleterious(0) | benign(0.326) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SDR42E1 | SNV | Missense_Mutation | c.142C>T | p.Pro48Ser | p.P48S | Q8WUS8 | protein_coding | tolerated(0.11) | benign(0.223) | TCGA-EA-A1QS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SDR42E1 | SNV | Missense_Mutation | c.523N>A | p.Asp175Asn | p.D175N | Q8WUS8 | protein_coding | tolerated(0.14) | benign(0) | TCGA-QL-A97D-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SDR42E1 | SNV | Missense_Mutation | c.969N>G | p.His323Gln | p.H323Q | Q8WUS8 | protein_coding | deleterious(0) | possibly_damaging(0.727) | TCGA-F5-6861-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SDR42E1 | SNV | Missense_Mutation | novel | c.413A>C | p.Glu138Ala | p.E138A | Q8WUS8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SDR42E1 | SNV | Missense_Mutation | rs545424632 | c.799N>T | p.Arg267Trp | p.R267W | Q8WUS8 | protein_coding | deleterious(0.03) | benign(0.351) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| SDR42E1 | SNV | Missense_Mutation | novel | c.376G>A | p.Val126Ile | p.V126I | Q8WUS8 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SDR42E1 | SNV | Missense_Mutation | novel | c.1132N>G | p.Ile378Val | p.I378V | Q8WUS8 | protein_coding | tolerated(1) | benign(0) | TCGA-AP-A1E1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SDR42E1 | SNV | Missense_Mutation | c.497N>T | p.Ala166Val | p.A166V | Q8WUS8 | protein_coding | deleterious(0.02) | possibly_damaging(0.862) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |